Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

Chapter 50 - Neuromuscular rehabilitation: diseases of the motor neuron, peripheral nerve, neuromuscular junction, and the muscle

from Section 7 - Disease-specific neurorehabilitation systems

References

1. Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000; 55: 388–92.
2. Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001; 22: 363–9.
3. Amosun SL, Ikuesan BA, Oloyede IJ. Rehabilitation of the handicapped child–what about the caregiver? PNG Med J 1995; 38: 208–14.
4. Mitsumoto H, Del Bene M. Improving the quality of life for people with ALS: the challenge ahead. Amyotroph Lateral Scler 2000; 1: 329–36.
5. Bromberg MB, Forshew DA. Comparison of instruments addressing quality of life in patients with ALS and their caregivers. Neurology 2002; 58: 320–2.
6. White C, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev 2004; 4: CD003904.
7. Abresch RT, Jensen MP, Carter GT. Health-related quality of life in peripheral neuropathy. Phys Med Rehabil Clin N Am 2001; 12: 461–72.
8. Abresch RT, Seyden NK, Wineinger MA. Quality of life. Issues for persons with neuromuscular diseases. Phys Med Rehabil Clin N Am 1998; 9: 233–48.
9. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000; 1: 293–9.
10. Kühnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol 2008; 4: 366–74.
11. Donaghy M. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J Neurol 1999; 246: 331–3.
12. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10: S2–9.
13. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003; 74: iv32–47.
14. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710–23.
15. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65: S3–9.
16. Tripathi VB, Al-Chalabi A. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2008; 7: 11–19.
17. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427: 801.
18. Shook SJ, Pioro EP. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Ann Neurol 2009; 65: S10–16.
19. Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2010; 10: 53–7.
20. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002; 2: CD001447.
21. Radunović A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 913–25.
22. Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009; 10: 378–83.
23. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002; 3: CD002064.
24. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009; 66: 227–34.
25. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71: 1770–5.
26. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45.
27. Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 481–90.
28. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008; 105: 2052–7.
29. Chiò A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010; 75: 619–25.
30. Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with myotrophic lateral sclerosis in 2 Danish counties. Neurology 1990; 40: 600–4.
31. Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler 2003; 4: 136–43.
32. Norquist JM, Jenkinson C. Fitzpatrick R, et al. Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Amyotroph Lateral Scler 2003; 4: 112–17.
33. McCluskey L. Palliative rehabilitation and amyotrophic lateral sclerosis: a perfect match. Neurorehabilitation 2007; 22: 407–8.
34. Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 2009; 65: S17–23.
35. Chiò A, Cucatto A, Calvo A, et al. Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. J Neurol 1999; 246: 175–80.
36. Miller RG, Anderson FA, Bradley WG, et al. The ALS patient care database: goals, design, and early results. Neurology 2000; 54: 53–7.
37. van den Berg JP, Kalmijn S, Lindeman E, et al. Rehabilitation care for patients with ALS in the Netherlands. Amyotroph Lateral Scler 2003; 4: 186–90.
38. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry 2003; 74: 1258–61.
39. Chiò A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology 1999; 53: 1123–5.
40. Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler 2003; 4: 177–85.
41. McKim DA, Road J, Avendano M, et al. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18: 197–215.
42. Miller RG, Jackson CE, Kasarskis EJ, et al. The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology 2009; 73: 1218–26.
43. Miller RG, Jackson CE, Kasarskis EJ, et al. The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology 2009; 73: 1227–33.
44. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004; 1: CD004156.
45. Drory VE, Goltsman E, Reznik JG, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133–7.
46. Trail M, Nelson N, Van JN, et al. Wheelchair use by patients with amyotrophic lateral sclerosis: a survey of user characteristics and selection preferences. Arch Phys Med Rehabil 2001; 82: 98–102.
47. Abresch RT, Carter GT, Jensen MP, et al. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Care 2002; 19: 39–48.
48. Shibata M, Abe K, Jimbo A, et al. Complex regional pain syndrome type I associated with amyotrophic lateral sclerosis. Clin J Pain 2003; 19: 69–70.
49. Kiebert GM, Green C, Murphy C, et al. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 87–93.
50. Maillot F, Laueriere L, Hazouard E, et al. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 57: 1939.
51. Pasetti C, Zanini G. The physician–patient relationship in amyotrophic lateral sclerosis. Neurol Sci 2000; 21: 318–23.
52. Carter GT, Bednar-Butler LM, Abresch RT, et al. Expanding the role of hospice care in amyotrophic lateral sclerosis. Am J Hosp Palliat Care 1999; 16: 707–10.
53. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol 2011; 68: 979–84.
54. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371: 2120–33.
55. Zerres K, Wirth B, Rudnik-Schoneborn S. Spinal muscular atrophy–clinical and genetic correlations. Neuromusc Disord 1997; 7: 202–7.
56. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15: 228–37.
57. Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003; 60: 1601–03.
58. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12: 2481–9.
59. Katsuno M, Banno H, Suzuki K, et al. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. Arch Neurol 2012; 69: 436–40.
60. Prior TW, Russman BS. Spinal muscular atrophy. In Pagon RA, Bird TD, Dolan CR, et al, eds. GeneReviews [Internet]. Seattle: University of Washington, 2000.
61. Ryan MM. The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatr Respir Rev 2008; 9: 51–4.
62. Fehlings DL, Kirsch S, McComas A, et al. Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy. Dev Med Child Neurol 2002; 44: 741–4.
63. McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. Phys Med Rehabil Clin N Am 1998; 9: 187–211.
64. Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Eur J Paediatr Neurol 2001; 5: 191–8.
65. Steffensen BF, Lyager S, Werge B, et al. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol 2002; 44: 623–32.
66. Koessler W, Wanke T, Winkler G, et al. 2 years' experience with inspiratory muscle training in patients with neuromuscular disorders. Chest 2001; 120: 765–9.
67. Lissoni A, Aliverti A, Tzeng AC, et al. Kinematic analysis of patients with spinal muscular atrophy during spontaneous breathing and mechanical ventilation. Am J Phys Med Rehabil 1998; 77: 188–92.
68. Robinson D, Galasko CS, Delaney C, et al. Scoliosis and lung function in spinal muscular atrophy. Eur Spine J 1995; 4: 268–73.
69. Bach JR, Zhitnikov S. The management of neuromuscular ventilatory failure. Semin Pediatr Neurol 1998; 5: 92–105.
70. Hardart MK, Burns JP, Truog RD. Respiratory support in spinal muscular atrophy type I: a survey of physician practices and attitudes. Pediatrics 2002; 110: e24.
71. Willig TN, Paulus J, Lacau Saint Guily J, et al. Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil 1994; 75: 1175–81.
72. Billard C, Gillet P, Barthez M, et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neurol 1998; 40: 12–20.
73. Fowler WM, Abresch RT, Koch TR, et al. Employment profiles in neuromuscular diseases. Am J Phys Med Rehabil 1997; 76: 26–37.
74. Mulder DW. Clinical observations on acute poliomyelitis. Ann N Y Acad Sci 1995; 753: 1–10.
75. Bruno RL. Paralytic vs. nonparalytic polio: distinction without a difference? Am J Phys Med Rehabil 2000; 79: 4–12.
76. Dalakas MC. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995; 753: 167–85.
77. Farbu E, Gilhus NE, Barnes MP, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006; 13: 795–801.
78. Jubelt B. Post-polio syndrome. Curr Treat Options Neurol 2004; 6: 87–93.
79. Sunnerhagen KS, Grimby G. Muscular effects in late polio. Acta Physiol Scand 2001; 171: 335–40.
80. Farbu E, Gilhus NE. Education, occupation, and perception of health amongst previous polio patients compared to their siblings. Eur J Neurol 2002; 9: 233–41.
81. Farbu E, Rekand T, Gilhus NE. Post-polio syndrome and total health status in a prospective hospital study. Eur J Neurol 2003; 10: 407–13.
82. Rekand T, Korv J, Farbu E, et al. Long-term outcome after poliomyelitis in different health and social conditions. J Epidemiol Commun Health 2003; 57: 368–72.
83. Schanke AK, Lobben B, Oyhaugen S. The Norwegian polio study 1994 part II: early experiences of polio and later psychosocial well-being. Spinal Cord 1999; 37: 515–21.
84. Kling C, Persson A, Gardulf A. The ADL ability and use of technical aids in persons with late effects of polio. Am J Occup Ther 2002; 56: 457–61.
85. Nollet F, Beelen A, Twisk JW, et al. Perceived health and physical functioning in postpoliomyelitis syndrome: a 6-year prospective follow-up study. Arch Phys Med Rehabil 2003; 84: 1048–56.
86. Pentland B, Hellawell D, Benjamin J, et al. Survey of the late consequences of polio in Edinburgh and the Lothians. Health Bull (Edin) 2000; 58: 267–75.
87. Ahuja B, Gupta VK, Tyagi A. Paralytic poliomyelitis (1989–1994): report from a sentinel center. Indian Pediatr 1996; 33: 739–45.
88. Burger H, Marincek C. The influence of post-polio syndrome on independence and life satisfaction. Disabil Rehabil 2000; 22: 318–22.
89. Kumakura N, Takayanagi M, Hasegawa T, et al. Self-assessed secondary difficulties among paralytic poliomyelitis and spinal cord injury survivors in Japan. Arch Phys Med Rehabil 2002; 83: 1245–51.
90. Larsson Lund M, Lexell J. A positive turning point in life – how persons with late effects of polio experience the influence of an interdisciplinary rehabilitation programme. J Rehabil Med 2010; 42: 559–65.
91. Nollet F, Beelen A, Sargeant AJ, et al. Submaximal exercise capacity and maximal power output in polio subjects. Arch Phys Med Rehabil 2001; 82: 1678–85.
92. Chan KM, Amirjani N, Sumrain M, et al. Randomized controlled trial of strength training in post-polio patients. Muscle Nerve 2003; 27: 332–8.
93. Agre JC, Rodriquez AA, Franke TM. Strength, endurance, and work capacity after muscle strengthening exercise in postpolio subjects. Arch Phys Med Rehabil 1997; 78: 681–6.
94. Spector SA, Gordon PL, Feuerstein IM, et al. Strength gains without muscle injury after strength training in patients with postpolio muscular atrophy. Muscle Nerve 1996; 19: 1282–90.
95. Klein MG, Whyte J, Esquenazi A, et al. A comparison of the effects of exercise and lifestyle modification on the resolution of overuse symptoms of the shoulder in polio survivors: a preliminary study. Arch Phys Med Rehabil 2002; 83: 708–13.
96. Willen C, Sunnerhagen KS, Grimby G. Dynamic water exercise in individuals with late poliomyelitis. Arch Phys Med Rehabil 2001; 82: 66–72.
97. Strumse YA, Stanghelle JK, Utne L, et al. (2003). Treatment of patients with postpolio syndrome in a warm climate. Disabil Rehabil 2003; 25: 77–84.
98. Bertelsen M, Broberg S, Madsen E. Outcome of physiotherapy as part of a multidisciplinary rehabilitation in an unselected polio population with one-year follow-up: an uncontrolled study. J Rehabil Med 2009; 41: 85–7.
99. Brogårdh C, Flansbjer UB, Lexell J. No effects of whole-body vibration training on muscle strength and gait performance in persons with late effects of polio: a pilot study. Arch Phys Med Rehabil 2010; 91: 1474–7.
100. Skough K, Krossén C, Heiwe S, et al. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil Med 2008; 40: 773–5.
101. Widar M, Ahlstrom G. Pain in persons with post-polio. The Swedish version of the multidimensional pain inventory (MPI). Scand J Caring Sci 1999; 13: 33–40.
102. Willen C, Grimby G. Pain, physical activity, and disability in individuals with late effects of polio. Arch Phys Med Rehabil 1998; 79: 915–19.
103. Vasiliadis HM, Collet JP, Shapiro S, et al. Predictive factors and correlates for pain in postpoliomyelitis syndrome patients. Arch Phys Med Rehabil 2002; 83: 1109–15.
104. Zapp JJ. Post-poliomyelitis pain treated with gabapentin. Am Fam Physician 1996; 53: 2442–45.
105. Trojan DA, Cashman N. R. Fibromyalgia is common in a postpoliomyelitis clinic. Arch Neurol 1995; 52: 620–4.
106. Ahlstrom G, Karlsson U. Disability and quality of life in individuals with postpolio syndrome. Disabil Rehabil 2000; 22: 416–22.
107. Thoren-Jonsson AL, Grimby G. Ability and perceived difficulty in daily activities in people with poliomyelitis sequelae. J Rehabil Med 2001; 33: 4–11.
108. McNeal DR, Somerville NJ, Wilson DJ. Work problems and accommodations reported by persons who are postpolio or have a spinal cord injury. Assist Technol 1999; 11: 137–57.
109. Lin MC, Liaw MY, Chen WJ, et al. Pulmonary function and spinal characteristics: their relationships in persons with idiopathic and postpoliomyelitic scoliosis. Arch Phys Med Rehabil 2001; 82: 335–41.
110. Weinberg J, Borg J, Bevegard S, et al. Respiratory response to exercise in postpolio patients with severe inspiratory muscle dysfunction. Arch Phys Med Rehabil 1999; 80: 1095–100.
111. Klefbeck B, Lagerstrand L, Mattsson E. Inspiratory muscle training in patients with prior polio who use part-time assisted ventilation. Arch Phys Med Rehabil 2000; 81: 1065–71.
112. Craig A, Moses P, Tran Y, et al. The effectiveness of a hands-free environmental control system for the profoundly disabled. Arch Phys Med Rehabil 2002; 83: 1455–8.
113. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci 1988; 21: 187–226.
114. Sheikh KA, Zang G. An update on pathobiologic roles of anti-glycan antibodies in Guillain–Barré sydrome. F1000 Biol Rep 2010; 2(pii): 21.
115. Hughes RA, Cornblath DR. Guillain–Barré syndrome. Lancet 2005; 366: 1653–66.
116. Lehmann HC, Meyer Zu Hörste G, Kieseier BC, et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009; 2: 261–81.
117. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 2008; 7: 939–50.
118. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain–Barre syndrome. Arch Neurol 2001; 58: 913–17.
119. Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30: 131–56.
120. Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 2007; 130: 2245–57.
121. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst Rev 6: 2010a; CD002063.
122. Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066–71.
123. Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain–Barre syndrome. Cochrane Database Syst Rev 2: 2002; CD001798.
124. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain–Barré syndrome. Cochrane Database Syst Rev 2: 2010; CD001446.
125. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barre syndrome: randomised trial. Lancet 2004; 363: 192–6.
126. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain–Barré syndrome. Arch Neurol 2005; 62: 1194–8.
127. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 2011; 76: 968–75.
128. Grand'Maison F, Feasby TE, Hahn AF, et al. Recurrent Guillain–Barre syndrome. Clinical and laboratory features. Brain 1992; 115: 1093–106.
129. Rees JH, Thompson RD, Smeeton NC, et al. Epidemiological study of Guillain–Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64: 74–7.
130. Melillo EM, Sethi JM, Mohsenin V. Guillain–Barre syndrome: rehabilitation outcome and recent developments. Yale J Biol Med 1998; 71: 383–9.
131. Sarada C, Tharakan JK, Nair M. Guillain–Barre syndrome: a prospective clinical study in 25 children and comparison with adults. Ann Trop Paediatr 1994; 14: 281–6.
132. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain–Barré syndrome. Ann Neurol 2010; 67: 781–7.
133. Govoni E, Granieri E. Epidemiology of the Guillain–Barré syndrome. Curr Opin Neurol 2001; 14: 605–13.
134. van Koningsveld R, van Doorn PA, Schmitz PI, et al. Mild forms of Guillain–Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000; 54: 620–5.
135. Cheng Q, Jiang GX, Fredrikson S., et al. Epidemiological surveillance of Guillain–Barre syndrome in Sweden, 1996–1997. Acta Neurol Scand 2000; 101: 104–10.
136. Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with Guillain–Barre syndrome requiring mechanical ventilation. Neurology 2000; 54: 2311–15.
137. Ropper AH. Severe acute Guillain–Barre syndrome. Neurology 1986; 36: 429–32.
138. Bernsen RA, de Jager AE, Schmitz PI, et al. Long-term impact on work and private life after Guillain–Barre syndrome. J Neurol Sci 2002; 201: 13–17.
139. Bersano A, Carpo M, Allaria S, et al. Long term disability and social status change after Guillain–Barré syndrome. J Neurol 2006; 253: 214–18.
140. Bernsen RA, de Jager AE, Kuijer W, et al. Psychosocial dysfunction in the first year after Guillain–Barré syndrome. Muscle Nerve 2010; 41: 533–9.
141. Khan F, Pallant JF, Ng L, et al. Factors associated with long-term functional outcomes and psychological sequelae in Guillain–Barre syndrome. J Neurol 2010; 257: 2024–31.
142. De Vries JM, Hagemans ML, Bussmann JB, et al. Fatigue in neuro-muscular disorders: focus on Guillain–Barré syndrome and Pompe disease. Cell Mol Life Sci 2010; 67: 701–13.
143. Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain–Barre syndrome. Intens Care Med 2000; 26: 1094–100.
144. Meythaler JM, DeVivo MJ, Braswell WC. Rehabilitation outcomes of patients who have developed Guillain–Barre syndrome. Am J Phys Med Rehabil 1997; 76: 411–9.
145. El Mhandi L, Calmels P, Camdessanché JP, et al. Muscle strength recovery in treated Guillain–Barré syndrome: a prospective study for the first 18 months after onset. Am J Phys Med Rehabil 2007; 86: 716–24.
146. Köller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343–56.
147. Lewis RA. Chronic inflammatory demyelinating polyneuropathy and other immune-mediated demyelinating neuropathies. Semin Neurol 2005; 25: 217–28.
148. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402–12.
149. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311–24.
150. Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011; 8: 48–58.
151. van Schaik IN, Winer JB, De Haan, R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 2: CD001797.
152. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 3: CD003906.
153. Joint Task Force of the EFNS and the PNS. Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15: 1–9.
154. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 1: CD002062.
155. Nobile-Orazio E, Gallia F, Tuccillo F, et al. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr Opin Neurol 2010; 23: 519–23.
156. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136–44.
157. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 802–7.
158. Donofrio PD, Bril V, Dalakas MC, et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082–8.
159. Bril V, Katzberg H, Donofrio P, et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009; 39: 448–55.
160. Bril V, Banach M, Dalakas MC, et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 2010; 42: 492–7.
161. Mahdi-Rogers M, Swan AV, van Doorn PA, et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2010; 11: CD003280.
162. Walk D, Li LY, Parry GJ, et al. Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology 2004; 62: 155–6.
163. Gorson KC, Amato AA, Ropper AH Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63: 715–17.
164. Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224: 29–35.
165. Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel(R)) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003; 210: 19–21.
166. Brannagan TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58: 1856–8.
167. Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006; 77, 800–2.
168. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257: 913–19.
169. Vermeulen M, van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72: 127–8.
170. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 485–9.
171. Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006; 77: 66–70.
172. Sghirlanzoni A, Solari A, Ciano C, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000; 21: 31–7.
173. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 52: 498–503.
174. Harbo T, Andersen H, Overgaard K, et al. Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2008; 13: 208–17.
175. Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol 2002; 249: 245–53.
176. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910–13.
177. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184: 57–63.
178. Bromberg MB, Feldman EL, Jaradeh S, et al. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Epidemiol 1992; 45: 47–52.
179. Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118: 359–68.
180. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321–8.
181. van Dijk GW, Notermans NC, Franssen H, et al. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol 1999; 246: 1134–9.
182. Verghese J, Bieri PL, Gellido C, et al. Peripheral neuropathy in young–old and old–old patients. Muscle Nerve 2001; 24: 1476–81.
183. Bolton CF, Young GB. Critical illness polyneuropathy. Curr Treat Options Neurol 2000; 2: 489–98.
184. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2011; 10: 931–41.
185. Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 2008; 79: 838–41.
186. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994; 17: 1494–5.
187. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intens Care Med 1997; 23: 1144–9.
188. Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 1012–16.
189. Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 160–73.
190. Pinzur MS. Diabetic peripheral neuropathy. Foot Ankle Clin 2011; 16: 345–9.
191. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. J Am Med Assoc 2003; 290: 1371–6.
192. Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007; 36: 144–66.
193. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol 2008; 21: 527–33.
194. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–93.
195. Tan M, Tan U. Early diagnosis of diabetic neuropathy using double-shock stimulation of peripheral nerves. Clin Neurophysiol 2003; 114: 1419–22.
196. Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108–11.
197. Arkkila PE, Gautier JF. Musculoskeletal disorders in diabetes mellitus: an update. Best Pract Res Clin Rheumatol 2003; 17: 945–70.
198. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011; 7: 208–20.
199. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000; 14: 65–70.
200. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81–104.
201. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy. Neurology 2011; 76: 1758–65.
202. Marchettini P, Teloni L, Formaglio F, et al. Pain in diabetic neuropathy case study: whole patient management. Eur J Neurol 2004; 11: 12–21.
203. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48–55.
204. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9–17.
205. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003; 63: 1549–63.
206. Cata JP, Cordella JV, Burton AW, et al. Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manage 2004; 27: 72–8.
207. De Baets MH. Insights in the autoimmunity of myasthenia gravis. Autoimmunity 2010; 43: 341–3.
208. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29: 484–505.
209. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004; 24: 31–9.
210. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475–90.
211. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005; 84: 627–38.
212. Hutchinson D, Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol 2008; 8: 229–37.
213. Katz J, Barohn RJ. Update on the evaluation and therapy of autoimmune neuromuscular junction disorders. Phys Med Rehabil Clin N Am 2001; 12: 381–97.
214. Sommer N, Melms A, Weller M, et al. Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84: 309–33.
215. Mantegazza R, Beghi E, Pareyson D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990; 237: 339–44.
216. Simpson JA, Thomaides T. Treatment of myasthenia gravis: an audit. Q J Med 1987; 64: 693–704.
217. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23: 489–95.
218. Newsom-Davis J. Lambert–Eaton myasthenic syndrome. Rev Neurol (Paris) 2004; 160: 177–80.
219. Sanders DB. Lambert–Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 2003; 998: 500–8.
220. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098–107.
221. Rich MM, Teener JW, Bird SJ. Treatment of Lambert–Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997; 20: 614–15.
222. Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton–Lambert syndrome. Ann Neurol 1982; 11: 570–5.
223. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6: 129–37.
224. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7: 297–306.
225. Cox S, Limaye V, Hill C, et al. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis 2010; 13: 117–24.
226. Hilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol 2001; 14: 591–6.
227. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2012; 11: 203–6.
228. Dimachkie MM. Idiopathic inflammatory myopathies. J Neuroimmunol 2011; 231: 32–42.
229. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol 2009; 21: 599–603.
230. Wiesinger GF, Quittan M, Aringer M, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37: 196–200.
231. Wiesinger GF, Quittan M, Graninger M, et al. Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998; 37: 1338–42.
232. Alexanderson H, Stenström CH, Jenner G, et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29: 295–301.
233. Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol 2005; 62: 1113–17.
234. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care 2005; 11: 126–32.
235. Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol 2009; 5: 372–9.
236. Green DM. Weakness in the ICU: Guillain–Barré syndrome, myasthenia gravis, and critical illness polyneuropathy/myopathy. Neurologist 2005; 11: 338–47.
237. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009; 373: 1874–82.
238. Gibson JN, Smith K, Rennie MJ. Prevention of disuse muscle atrophy by means of electrical stimulation: maintenance of protein synthesis. Lancet 1988; 2: 767–70.
239. Gerovasili V, Stefanidis K, Vitzilaios K, et al. Electrical muscle stimulation preserves the muscle mass of critically ill patients: a randomized study. Crit Care 2009; 13: R161.
240. Needham DM, Truong AD, Fan E. Technology to enhance physical rehabilitation of critically ill patients. Crit Care Med 2009; 37: S436–41.
241. Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med 2009; 37: 2499–505.
242. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838–45.
243. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055–66.
244. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double- blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067–77.
245. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445–9.
246. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50, 195–201.
247. Dyck PJ, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35: 1173–6.
248. Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53: 57–61.
249. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249: 1370–7.
250. Federico P, Zochodne DW, Hahn AF, et al. (2000). Multifocal motor neuropathy improved by IV Ig: randomized, double-blind, placebo-controlled study. Neurology 2000; 55: 1256–62.